JP2019530695A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019530695A5 JP2019530695A5 JP2019518219A JP2019518219A JP2019530695A5 JP 2019530695 A5 JP2019530695 A5 JP 2019530695A5 JP 2019518219 A JP2019518219 A JP 2019518219A JP 2019518219 A JP2019518219 A JP 2019518219A JP 2019530695 A5 JP2019530695 A5 JP 2019530695A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- imidazole
- pyridin
- phenyl
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 N (CH 3 ) 2 Chemical group 0.000 claims description 1015
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims description 934
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 425
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 195
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 184
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 120
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 118
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 114
- 125000000217 alkyl group Chemical group 0.000 claims description 101
- 150000002460 imidazoles Chemical class 0.000 claims description 98
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 76
- 150000001875 compounds Chemical class 0.000 claims description 75
- 150000003839 salts Chemical class 0.000 claims description 44
- 239000012453 solvate Substances 0.000 claims description 43
- 150000001204 N-oxides Chemical class 0.000 claims description 40
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 36
- 125000005843 halogen group Chemical group 0.000 claims description 33
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 27
- 125000004076 pyridyl group Chemical group 0.000 claims description 27
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 25
- 125000001544 thienyl group Chemical group 0.000 claims description 23
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 22
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 20
- 125000003566 oxetanyl group Chemical group 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 125000000335 thiazolyl group Chemical group 0.000 claims description 18
- FPGGLMIYNLQOID-UHFFFAOYSA-N 3h-pyridin-2-one Chemical compound O=C1CC=CC=N1 FPGGLMIYNLQOID-UHFFFAOYSA-N 0.000 claims description 16
- 125000003386 piperidinyl group Chemical group 0.000 claims description 16
- 125000001188 haloalkyl group Chemical group 0.000 claims description 15
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 14
- 125000002393 azetidinyl group Chemical group 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 13
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims description 12
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims description 12
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 12
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 12
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 10
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 10
- 125000002757 morpholinyl group Chemical group 0.000 claims description 10
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 10
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 8
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 8
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 8
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 8
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 7
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 claims description 7
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 6
- 125000004791 2-fluoroethoxy group Chemical group FCCO* 0.000 claims description 6
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 6
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 6
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 6
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 6
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 6
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 6
- 125000001425 triazolyl group Chemical group 0.000 claims description 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 5
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 4
- 125000004361 3,4,5-trifluorophenyl group Chemical group [H]C1=C(F)C(F)=C(F)C([H])=C1* 0.000 claims description 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 4
- 208000020925 Bipolar disease Diseases 0.000 claims description 4
- 102000034527 Retinoid X Receptors Human genes 0.000 claims description 4
- 108010038912 Retinoid X Receptors Proteins 0.000 claims description 4
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims description 4
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 230000000155 isotopic effect Effects 0.000 claims description 4
- 208000024714 major depressive disease Diseases 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- WGSXKYXKAARAKD-UHFFFAOYSA-N 1-fluoro-3-isocyanato-5-(trifluoromethyl)benzene Chemical group FC1=CC(N=C=O)=CC(C(F)(F)F)=C1 WGSXKYXKAARAKD-UHFFFAOYSA-N 0.000 claims description 2
- 125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 2
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- YYFAXNDGFHTVEQ-UHFFFAOYSA-N 6-[3-(dimethylamino)phenyl]-1-[(3-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-one Chemical compound CN(C=1C=C(C=CC=1)C=1C=C2C(=NC=1)NC(N2CC1=CC(=CC=C1)F)=O)C YYFAXNDGFHTVEQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
- 206010003805 Autism Diseases 0.000 claims description 2
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- VDNCCWWMTPZKLW-UHFFFAOYSA-N CC(C(F)=C(C=C1)C(N=CC(CN2C=CN(C)C2)=C2)=C2F)=C1F Chemical compound CC(C(F)=C(C=C1)C(N=CC(CN2C=CN(C)C2)=C2)=C2F)=C1F VDNCCWWMTPZKLW-UHFFFAOYSA-N 0.000 claims description 2
- LUMWMOUZWYIEPS-UHFFFAOYSA-N CC(C(F)=C(C=C1)C(N=CC(CN2C=CNC2)=C2)=C2F)=C1F Chemical compound CC(C(F)=C(C=C1)C(N=CC(CN2C=CNC2)=C2)=C2F)=C1F LUMWMOUZWYIEPS-UHFFFAOYSA-N 0.000 claims description 2
- NDDWQZFAUIYOKC-UHFFFAOYSA-N CC(C(F)=C(C=C1)C2=CC(CN3C=CN(C)C3)=CC=N2)=C1F Chemical compound CC(C(F)=C(C=C1)C2=CC(CN3C=CN(C)C3)=CC=N2)=C1F NDDWQZFAUIYOKC-UHFFFAOYSA-N 0.000 claims description 2
- DIQRPXCHJWETIZ-UHFFFAOYSA-N CC(C(F)=C(C=C1)C2=CC(CN3C=CN(C)C3)=NC=N2)=C1F Chemical compound CC(C(F)=C(C=C1)C2=CC(CN3C=CN(C)C3)=NC=N2)=C1F DIQRPXCHJWETIZ-UHFFFAOYSA-N 0.000 claims description 2
- FYYAFSAZURGINV-UHFFFAOYSA-N CC(C(F)=C(C=C1)C2=CC=C(CN3C=CN(C)C3)C=N2)=C1F Chemical compound CC(C(F)=C(C=C1)C2=CC=C(CN3C=CN(C)C3)C=N2)=C1F FYYAFSAZURGINV-UHFFFAOYSA-N 0.000 claims description 2
- NVLZXDFDEZFFHL-UHFFFAOYSA-N CC(C(F)=C(C=C1)C2=CC=C(CN3C=CN(C)C3)N=N2)=C1F Chemical compound CC(C(F)=C(C=C1)C2=CC=C(CN3C=CN(C)C3)N=N2)=C1F NVLZXDFDEZFFHL-UHFFFAOYSA-N 0.000 claims description 2
- HATKYCOQCLJGDM-UHFFFAOYSA-N CC(C(F)=C(C=C1)C2=CC=C(CN3C=CNC3)C=N2)=C1F Chemical compound CC(C(F)=C(C=C1)C2=CC=C(CN3C=CNC3)C=N2)=C1F HATKYCOQCLJGDM-UHFFFAOYSA-N 0.000 claims description 2
- QJCBGIGRZMTPEE-UHFFFAOYSA-N CC(C(F)=C(C=C1)C2=CC=CC(CN3C=CN(C)C3)=N2)=C1F Chemical compound CC(C(F)=C(C=C1)C2=CC=CC(CN3C=CN(C)C3)=N2)=C1F QJCBGIGRZMTPEE-UHFFFAOYSA-N 0.000 claims description 2
- RBYJCRRIZAPJFM-UHFFFAOYSA-N CC(C(F)=C(C=C1)C2=CC=CC(CN3C=CNC3)=N2)=C1F Chemical compound CC(C(F)=C(C=C1)C2=CC=CC(CN3C=CNC3)=N2)=C1F RBYJCRRIZAPJFM-UHFFFAOYSA-N 0.000 claims description 2
- YKMPOMMGNFMMKL-UHFFFAOYSA-N CC(C(F)=C(C=C1)C2=CC=NC(CN3C=CN(C)C3)=N2)=C1F Chemical compound CC(C(F)=C(C=C1)C2=CC=NC(CN3C=CN(C)C3)=N2)=C1F YKMPOMMGNFMMKL-UHFFFAOYSA-N 0.000 claims description 2
- HNZZXISYCOKUSZ-UHFFFAOYSA-N CC(C(F)=C(C=C1)C2=CN=CC(CN3C=CN(C)C3)=N2)=C1F Chemical compound CC(C(F)=C(C=C1)C2=CN=CC(CN3C=CN(C)C3)=N2)=C1F HNZZXISYCOKUSZ-UHFFFAOYSA-N 0.000 claims description 2
- YNFAXOJLGWCAGH-UHFFFAOYSA-N CC(C)(C)C(C=C1)=CC=C1C(N=C1CN2C=CNC2)=CC(OC)=C1OC Chemical compound CC(C)(C)C(C=C1)=CC=C1C(N=C1CN2C=CNC2)=CC(OC)=C1OC YNFAXOJLGWCAGH-UHFFFAOYSA-N 0.000 claims description 2
- CKKAHBVMMYALCU-UHFFFAOYSA-N CC(C)C1=CC=C(CN2C=CNC2)C(C(C=C2)=CC=C2Cl)=C1 Chemical compound CC(C)C1=CC=C(CN2C=CNC2)C(C(C=C2)=CC=C2Cl)=C1 CKKAHBVMMYALCU-UHFFFAOYSA-N 0.000 claims description 2
- YXXTXMGGTXHGBU-UHFFFAOYSA-N CC(C=C(C(N=CC(CN1C=CN(C)C1)=C1)=C1Cl)S1)=C1Cl Chemical compound CC(C=C(C(N=CC(CN1C=CN(C)C1)=C1)=C1Cl)S1)=C1Cl YXXTXMGGTXHGBU-UHFFFAOYSA-N 0.000 claims description 2
- USCVPDDIAZGYFQ-UHFFFAOYSA-N CC(C=C(C1=CC=C(CN2C=CN(C)C2)C=N1)S1)=C1Cl Chemical compound CC(C=C(C1=CC=C(CN2C=CN(C)C2)C=N1)S1)=C1Cl USCVPDDIAZGYFQ-UHFFFAOYSA-N 0.000 claims description 2
- GGZUPCQYAXRKGM-UHFFFAOYSA-N CC(C=C(C=C1)C(N=CC(CN2C=CN(C)C2)=C2)=C2F)=C1F Chemical compound CC(C=C(C=C1)C(N=CC(CN2C=CN(C)C2)=C2)=C2F)=C1F GGZUPCQYAXRKGM-UHFFFAOYSA-N 0.000 claims description 2
- VTTHBOSYTYIOIC-UHFFFAOYSA-N CC(C=C(C=C1)C(N=CC(CN2C=CNC2)=C2)=C2F)=C1Cl Chemical compound CC(C=C(C=C1)C(N=CC(CN2C=CNC2)=C2)=C2F)=C1Cl VTTHBOSYTYIOIC-UHFFFAOYSA-N 0.000 claims description 2
- KKWJEBADUWRQQX-UHFFFAOYSA-N CC(C=C(C=C1)C(N=CC(CN2C=CNC2)=C2)=C2F)=C1F Chemical compound CC(C=C(C=C1)C(N=CC(CN2C=CNC2)=C2)=C2F)=C1F KKWJEBADUWRQQX-UHFFFAOYSA-N 0.000 claims description 2
- KEQMUQVVDDWZKZ-UHFFFAOYSA-N CC(C=C(C=C1)C2=C(C)C=C(CN3C=CNC3)C=N2)=C1F Chemical compound CC(C=C(C=C1)C2=C(C)C=C(CN3C=CNC3)C=N2)=C1F KEQMUQVVDDWZKZ-UHFFFAOYSA-N 0.000 claims description 2
- XDMQEOZDKMAAOA-UHFFFAOYSA-N CC(C=C(C=C1)C2=C(CN3C=CN(C)C3)C=NC=N2)=C1F Chemical compound CC(C=C(C=C1)C2=C(CN3C=CN(C)C3)C=NC=N2)=C1F XDMQEOZDKMAAOA-UHFFFAOYSA-N 0.000 claims description 2
- IVFUPYPUUMMEPF-UHFFFAOYSA-N CC(C=C(C=C1)C2=CC(CN3C=CN(C)C3)=CC=N2)=C1F Chemical compound CC(C=C(C=C1)C2=CC(CN3C=CN(C)C3)=CC=N2)=C1F IVFUPYPUUMMEPF-UHFFFAOYSA-N 0.000 claims description 2
- PKSDFCPSUKUPPC-UHFFFAOYSA-N CC(C=C(C=C1)C2=CC(CN3C=CN(C)C3)=NC=N2)=C1F Chemical compound CC(C=C(C=C1)C2=CC(CN3C=CN(C)C3)=NC=N2)=C1F PKSDFCPSUKUPPC-UHFFFAOYSA-N 0.000 claims description 2
- TWFNAGIRPUVXJE-UHFFFAOYSA-N CC(C=C(C=C1)C2=CC=C(CN3C=CN(C)C3)C=N2)=C1F Chemical compound CC(C=C(C=C1)C2=CC=C(CN3C=CN(C)C3)C=N2)=C1F TWFNAGIRPUVXJE-UHFFFAOYSA-N 0.000 claims description 2
- WQOOORXIMAGESM-UHFFFAOYSA-N CC(C=C(C=C1)C2=CC=C(CN3C=CN(C)C3)N=N2)=C1F Chemical compound CC(C=C(C=C1)C2=CC=C(CN3C=CN(C)C3)N=N2)=C1F WQOOORXIMAGESM-UHFFFAOYSA-N 0.000 claims description 2
- DYXGQCDRBSGLSF-UHFFFAOYSA-N CC(C=C(C=C1)C2=CC=C(CN3C=CNC3)C=N2)=C1F Chemical compound CC(C=C(C=C1)C2=CC=C(CN3C=CNC3)C=N2)=C1F DYXGQCDRBSGLSF-UHFFFAOYSA-N 0.000 claims description 2
- WSFBQRMKQICRJG-UHFFFAOYSA-N CC(C=C(C=C1)C2=CC=CC(CN3C=CN(C)C3)=N2)=C1F Chemical compound CC(C=C(C=C1)C2=CC=CC(CN3C=CN(C)C3)=N2)=C1F WSFBQRMKQICRJG-UHFFFAOYSA-N 0.000 claims description 2
- GDFOOKZDMIRSDT-UHFFFAOYSA-N CC(C=C(C=C1)C2=CC=CC(CN3C=CNC3)=N2)=C1F Chemical compound CC(C=C(C=C1)C2=CC=CC(CN3C=CNC3)=N2)=C1F GDFOOKZDMIRSDT-UHFFFAOYSA-N 0.000 claims description 2
- PXWSNWWUGKPPHO-UHFFFAOYSA-N CC(C=C(C=C1)C2=CC=NC(CN3C=CN(C)C3)=N2)=C1F Chemical compound CC(C=C(C=C1)C2=CC=NC(CN3C=CN(C)C3)=N2)=C1F PXWSNWWUGKPPHO-UHFFFAOYSA-N 0.000 claims description 2
- WAARRNFWILCTJZ-UHFFFAOYSA-N CC(C=C(C=C1)C2=CN=CC(CN3C=CN(C)C3)=N2)=C1F Chemical compound CC(C=C(C=C1)C2=CN=CC(CN3C=CN(C)C3)=N2)=C1F WAARRNFWILCTJZ-UHFFFAOYSA-N 0.000 claims description 2
- FNHYEQWIUAKLJS-UHFFFAOYSA-N CC(C=C(C=C1)F)=C1C1=CC(F)=CC=C1CN1C=CNC1 Chemical compound CC(C=C(C=C1)F)=C1C1=CC(F)=CC=C1CN1C=CNC1 FNHYEQWIUAKLJS-UHFFFAOYSA-N 0.000 claims description 2
- AATAKQWBSZPJAC-UHFFFAOYSA-N CC(C=C1)=CC=C1C1=CC=CC(CN2C=CNC2)=N1 Chemical compound CC(C=C1)=CC=C1C1=CC=CC(CN2C=CNC2)=N1 AATAKQWBSZPJAC-UHFFFAOYSA-N 0.000 claims description 2
- XCTVEFKPLJZNOP-UHFFFAOYSA-N CC1=C(C(C=C2)=CC(C(F)(F)F)=C2F)N=CC(CN2C=CNC2)=C1 Chemical compound CC1=C(C(C=C2)=CC(C(F)(F)F)=C2F)N=CC(CN2C=CNC2)=C1 XCTVEFKPLJZNOP-UHFFFAOYSA-N 0.000 claims description 2
- OBMNBZZRLUVPDR-UHFFFAOYSA-N CC1=C(C(C=C2)=CC(F)=C2F)N=CC(CN2C=CNC2)=C1 Chemical compound CC1=C(C(C=C2)=CC(F)=C2F)N=CC(CN2C=CNC2)=C1 OBMNBZZRLUVPDR-UHFFFAOYSA-N 0.000 claims description 2
- GSPHNVDIOHUYFS-UHFFFAOYSA-N CC1=C(C(C=CC(F)=C2C)=C2F)N=CC(CN2C=CNC2)=C1 Chemical compound CC1=C(C(C=CC(F)=C2C)=C2F)N=CC(CN2C=CNC2)=C1 GSPHNVDIOHUYFS-UHFFFAOYSA-N 0.000 claims description 2
- JZNVEKIOIYNOMR-UHFFFAOYSA-N CC1=C(C(C=CC=C2F)=C2F)N=CC(CN2C=CNC2)=C1 Chemical compound CC1=C(C(C=CC=C2F)=C2F)N=CC(CN2C=CNC2)=C1 JZNVEKIOIYNOMR-UHFFFAOYSA-N 0.000 claims description 2
- WHPWLKRWSWSUAV-UHFFFAOYSA-N CC1=C(C2=CC(Cl)=CC=C2)N=CC(CN2C=CNC2)=C1 Chemical compound CC1=C(C2=CC(Cl)=CC=C2)N=CC(CN2C=CNC2)=C1 WHPWLKRWSWSUAV-UHFFFAOYSA-N 0.000 claims description 2
- ZEWLSTHRTIANOS-UHFFFAOYSA-N CC1=C(C2=CC(F)=CC(F)=C2)N=CC(CN2C=CNC2)=C1 Chemical compound CC1=C(C2=CC(F)=CC(F)=C2)N=CC(CN2C=CNC2)=C1 ZEWLSTHRTIANOS-UHFFFAOYSA-N 0.000 claims description 2
- RBEWHXSVLJUYFE-UHFFFAOYSA-N CC1=C(C2=CC(F)=CC=C2)N=CC(CN2C=CNC2)=C1 Chemical compound CC1=C(C2=CC(F)=CC=C2)N=CC(CN2C=CNC2)=C1 RBEWHXSVLJUYFE-UHFFFAOYSA-N 0.000 claims description 2
- CQNUIYSMLGAHCY-UHFFFAOYSA-N CC1=C(CN2C=CNC2)C=NC(C(C=C2)=CC(C(F)(F)F)=C2F)=C1 Chemical compound CC1=C(CN2C=CNC2)C=NC(C(C=C2)=CC(C(F)(F)F)=C2F)=C1 CQNUIYSMLGAHCY-UHFFFAOYSA-N 0.000 claims description 2
- PGIKAIYIBRJNQC-UHFFFAOYSA-N CC1=C(CN2C=CNC2)C=NC(C(C=C2)=CC(C)=C2F)=C1 Chemical compound CC1=C(CN2C=CNC2)C=NC(C(C=C2)=CC(C)=C2F)=C1 PGIKAIYIBRJNQC-UHFFFAOYSA-N 0.000 claims description 2
- FDZSZPHXVMZZCS-UHFFFAOYSA-N CC1=C(CN2C=CNC2)C=NC(C(C=C2)=CC(F)=C2F)=C1 Chemical compound CC1=C(CN2C=CNC2)C=NC(C(C=C2)=CC(F)=C2F)=C1 FDZSZPHXVMZZCS-UHFFFAOYSA-N 0.000 claims description 2
- QCFOCPXMQSDSID-UHFFFAOYSA-N CC1=C(CN2C=CNC2)C=NC(C(C=CC(F)=C2C)=C2F)=C1 Chemical compound CC1=C(CN2C=CNC2)C=NC(C(C=CC(F)=C2C)=C2F)=C1 QCFOCPXMQSDSID-UHFFFAOYSA-N 0.000 claims description 2
- IZXNDZWYBDEKST-UHFFFAOYSA-N CC1=C(CN2C=CNC2)C=NC(C2=CC(F)=CC=C2)=C1 Chemical compound CC1=C(CN2C=CNC2)C=NC(C2=CC(F)=CC=C2)=C1 IZXNDZWYBDEKST-UHFFFAOYSA-N 0.000 claims description 2
- AUGLTMMUKGIVGQ-UHFFFAOYSA-N CC1=CC(C)=CC(C(C(CN2C=CNC2)=C2)=CC=C2F)=C1 Chemical compound CC1=CC(C)=CC(C(C(CN2C=CNC2)=C2)=CC=C2F)=C1 AUGLTMMUKGIVGQ-UHFFFAOYSA-N 0.000 claims description 2
- UZJCFUAEKMMDDF-UHFFFAOYSA-N CC1=CC(C2=CC=C(CN3C=CN(C)C3)C=N2)=CC=C1 Chemical compound CC1=CC(C2=CC=C(CN3C=CN(C)C3)C=N2)=CC=C1 UZJCFUAEKMMDDF-UHFFFAOYSA-N 0.000 claims description 2
- JFVPWGXZHYEUKT-UHFFFAOYSA-N CC1=CC(C2=CC=C(CN3C=CN(C)C3)N=N2)=CC(F)=C1 Chemical compound CC1=CC(C2=CC=C(CN3C=CN(C)C3)N=N2)=CC(F)=C1 JFVPWGXZHYEUKT-UHFFFAOYSA-N 0.000 claims description 2
- QBVDRTROXYKPBT-UHFFFAOYSA-N CC1=CC(C2=CC=C(CN3C=CN(C)C3)N=N2)=CC=C1 Chemical compound CC1=CC(C2=CC=C(CN3C=CN(C)C3)N=N2)=CC=C1 QBVDRTROXYKPBT-UHFFFAOYSA-N 0.000 claims description 2
- FEDOZNWMZJEVQK-UHFFFAOYSA-N CC1=CC(C2=CC=C(CN3C=CNC3)C=N2)=CC=C1 Chemical compound CC1=CC(C2=CC=C(CN3C=CNC3)C=N2)=CC=C1 FEDOZNWMZJEVQK-UHFFFAOYSA-N 0.000 claims description 2
- XIXNIXDMMXUTGY-UHFFFAOYSA-N CC1=CC=C(C(C=C2)=CC(C)=C2F)N=C1CN1C=CNC1 Chemical compound CC1=CC=C(C(C=C2)=CC(C)=C2F)N=C1CN1C=CNC1 XIXNIXDMMXUTGY-UHFFFAOYSA-N 0.000 claims description 2
- QLIGLVYGMXTRQM-UHFFFAOYSA-N CC1=CC=C(C(C=C2)=CC(F)=C2F)N=C1CN1C=CNC1 Chemical compound CC1=CC=C(C(C=C2)=CC(F)=C2F)N=C1CN1C=CNC1 QLIGLVYGMXTRQM-UHFFFAOYSA-N 0.000 claims description 2
- VTDCSDXXFJFLQA-UHFFFAOYSA-N CC1=CC=C(C(C=CC(F)=C2C)=C2F)N=C1CN1C=CNC1 Chemical compound CC1=CC=C(C(C=CC(F)=C2C)=C2F)N=C1CN1C=CNC1 VTDCSDXXFJFLQA-UHFFFAOYSA-N 0.000 claims description 2
- MLYPPEHLELXELH-UHFFFAOYSA-N CC1=CC=C(C(C=CC=C2F)=C2F)N=C1CN1C=CNC1 Chemical compound CC1=CC=C(C(C=CC=C2F)=C2F)N=C1CN1C=CNC1 MLYPPEHLELXELH-UHFFFAOYSA-N 0.000 claims description 2
- AOKVTDVHHAISMF-UHFFFAOYSA-N CC1=CC=C(C2=CC(F)=CC(F)=C2)N=C1CN1C=CNC1 Chemical compound CC1=CC=C(C2=CC(F)=CC(F)=C2)N=C1CN1C=CNC1 AOKVTDVHHAISMF-UHFFFAOYSA-N 0.000 claims description 2
- PDAZZZVZMADIQU-UHFFFAOYSA-N CC1=CC=C(C2=CC(F)=CC=C2)N=C1CN1C=CNC1 Chemical compound CC1=CC=C(C2=CC(F)=CC=C2)N=C1CN1C=CNC1 PDAZZZVZMADIQU-UHFFFAOYSA-N 0.000 claims description 2
- UESRPCCXNKOIRR-UHFFFAOYSA-N CC1=CC=CC(C(N=CC(CN2C=CN(C)C2)=C2)=C2F)=C1F Chemical compound CC1=CC=CC(C(N=CC(CN2C=CN(C)C2)=C2)=C2F)=C1F UESRPCCXNKOIRR-UHFFFAOYSA-N 0.000 claims description 2
- AAKGAIXZVDKGHB-UHFFFAOYSA-N CC1=CC=CC(C2=CC=C(CN3C=CN(C)C3)C=N2)=C1F Chemical compound CC1=CC=CC(C2=CC=C(CN3C=CN(C)C3)C=N2)=C1F AAKGAIXZVDKGHB-UHFFFAOYSA-N 0.000 claims description 2
- COJSNLABYCKAFC-UHFFFAOYSA-N CCOC(C=CC(F)=C1)=C1C(C(CN1C=CNC1)=C1)=CC=C1F Chemical compound CCOC(C=CC(F)=C1)=C1C(C(CN1C=CNC1)=C1)=CC=C1F COJSNLABYCKAFC-UHFFFAOYSA-N 0.000 claims description 2
- AUDMNNPFJIPBDY-UHFFFAOYSA-N CCOC(C=CC=C1)=C1C(C(CN1C=CNC1)=C1)=CC=C1F Chemical compound CCOC(C=CC=C1)=C1C(C(CN1C=CNC1)=C1)=CC=C1F AUDMNNPFJIPBDY-UHFFFAOYSA-N 0.000 claims description 2
- HDQZEPMLLOUWAL-UHFFFAOYSA-N CCOC(C=CC=C1)=C1C(C(CN1C=CNC1)=C1)=CC=C1OC Chemical compound CCOC(C=CC=C1)=C1C(C(CN1C=CNC1)=C1)=CC=C1OC HDQZEPMLLOUWAL-UHFFFAOYSA-N 0.000 claims description 2
- YQPAPNTUJQGUKR-UHFFFAOYSA-N CCOC(C=CC=C1)=C1C1=CC(F)=CC=C1CN1C=CNC1 Chemical compound CCOC(C=CC=C1)=C1C1=CC(F)=CC=C1CN1C=CNC1 YQPAPNTUJQGUKR-UHFFFAOYSA-N 0.000 claims description 2
- DFSCHQNWLIOGFM-UHFFFAOYSA-N CCOC(C=CC=C1)=C1C1=CC=CC(F)=C1CN1C=CNC1 Chemical compound CCOC(C=CC=C1)=C1C1=CC=CC(F)=C1CN1C=CNC1 DFSCHQNWLIOGFM-UHFFFAOYSA-N 0.000 claims description 2
- SFUZQZRXJZWRJB-UHFFFAOYSA-N CN1C=CN(CC2=C(C(C=C3)=CC(F)=C3F)N=CN=C2)C1 Chemical compound CN1C=CN(CC2=C(C(C=C3)=CC(F)=C3F)N=CN=C2)C1 SFUZQZRXJZWRJB-UHFFFAOYSA-N 0.000 claims description 2
- WMIVQZLERJLLLQ-UHFFFAOYSA-N CN1C=CN(CC2=C(C3=CC(F)=CC=C3)N=CN=C2)C1 Chemical compound CN1C=CN(CC2=C(C3=CC(F)=CC=C3)N=CN=C2)C1 WMIVQZLERJLLLQ-UHFFFAOYSA-N 0.000 claims description 2
- OOWVRTNUBVCCQV-UHFFFAOYSA-N CN1C=CN(CC2=CC(F)=C(C(C=C3)=CC(C(F)F)=C3F)N=C2)C1 Chemical compound CN1C=CN(CC2=CC(F)=C(C(C=C3)=CC(C(F)F)=C3F)N=C2)C1 OOWVRTNUBVCCQV-UHFFFAOYSA-N 0.000 claims description 2
- XLWFGNFEYMMBQU-UHFFFAOYSA-N CN1C=CN(CC2=CC(F)=C(C(C=C3)=CC(Cl)=C3Cl)N=C2)C1 Chemical compound CN1C=CN(CC2=CC(F)=C(C(C=C3)=CC(Cl)=C3Cl)N=C2)C1 XLWFGNFEYMMBQU-UHFFFAOYSA-N 0.000 claims description 2
- YGPPUEZWWAQZHX-UHFFFAOYSA-N CN1C=CN(CC2=CC(F)=C(C(C=C3)=CC(F)=C3F)N=C2)C1 Chemical compound CN1C=CN(CC2=CC(F)=C(C(C=C3)=CC(F)=C3F)N=C2)C1 YGPPUEZWWAQZHX-UHFFFAOYSA-N 0.000 claims description 2
- ZQQWPZPGAZTGDJ-UHFFFAOYSA-N CN1C=CN(CC2=CC(F)=C(C(C=C3)=CC(OC(F)F)=C3Cl)N=C2)C1 Chemical compound CN1C=CN(CC2=CC(F)=C(C(C=C3)=CC(OC(F)F)=C3Cl)N=C2)C1 ZQQWPZPGAZTGDJ-UHFFFAOYSA-N 0.000 claims description 2
- IPOQOLGVOUQJSD-UHFFFAOYSA-N CN1C=CN(CC2=CC(F)=C(C(C=C3)=CC(OC(F)F)=C3F)N=C2)C1 Chemical compound CN1C=CN(CC2=CC(F)=C(C(C=C3)=CC(OC(F)F)=C3F)N=C2)C1 IPOQOLGVOUQJSD-UHFFFAOYSA-N 0.000 claims description 2
- SDARLSQYGCPYNE-UHFFFAOYSA-N CN1C=CN(CC2=CC(F)=C(C(C=CC=C3Cl)=C3F)N=C2)C1 Chemical compound CN1C=CN(CC2=CC(F)=C(C(C=CC=C3Cl)=C3F)N=C2)C1 SDARLSQYGCPYNE-UHFFFAOYSA-N 0.000 claims description 2
- RECWMYHIINTZDH-UHFFFAOYSA-N CN1C=CN(CC2=CC(F)=C(C(C=CC=C3F)=C3F)N=C2)C1 Chemical compound CN1C=CN(CC2=CC(F)=C(C(C=CC=C3F)=C3F)N=C2)C1 RECWMYHIINTZDH-UHFFFAOYSA-N 0.000 claims description 2
- GDEGTIMYQLNJIQ-UHFFFAOYSA-N CN1C=CN(CC2=CC(F)=C(C3=CC(Cl)=CC=C3)N=C2)C1 Chemical compound CN1C=CN(CC2=CC(F)=C(C3=CC(Cl)=CC=C3)N=C2)C1 GDEGTIMYQLNJIQ-UHFFFAOYSA-N 0.000 claims description 2
- CHMRINDLQUJOHF-UHFFFAOYSA-N CN1C=CN(CC2=CC(F)=C(C3=CC(OC(F)F)=CC=C3)N=C2)C1 Chemical compound CN1C=CN(CC2=CC(F)=C(C3=CC(OC(F)F)=CC=C3)N=C2)C1 CHMRINDLQUJOHF-UHFFFAOYSA-N 0.000 claims description 2
- UQJQJZAXXUWBFG-UHFFFAOYSA-N CN1C=CN(CC2=CC=C(C(C=C3)=CC(C(F)(F)F)=C3Cl)N=N2)C1 Chemical compound CN1C=CN(CC2=CC=C(C(C=C3)=CC(C(F)(F)F)=C3Cl)N=N2)C1 UQJQJZAXXUWBFG-UHFFFAOYSA-N 0.000 claims description 2
- AUNQOOKBVULXQU-UHFFFAOYSA-N CN1C=CN(CC2=CC=C(C(C=C3)=CC(C(F)(F)F)=C3F)N=C2)C1 Chemical compound CN1C=CN(CC2=CC=C(C(C=C3)=CC(C(F)(F)F)=C3F)N=C2)C1 AUNQOOKBVULXQU-UHFFFAOYSA-N 0.000 claims description 2
- VBJFFFKNKYPXHW-UHFFFAOYSA-N CN1C=CN(CC2=CC=C(C(C=C3)=CC(C(F)(F)F)=C3F)N=N2)C1 Chemical compound CN1C=CN(CC2=CC=C(C(C=C3)=CC(C(F)(F)F)=C3F)N=N2)C1 VBJFFFKNKYPXHW-UHFFFAOYSA-N 0.000 claims description 2
- AATTXPOEAJTHHM-UHFFFAOYSA-N CN1C=CN(CC2=CC=C(C(C=C3)=CC(C(F)F)=C3F)N=N2)C1 Chemical compound CN1C=CN(CC2=CC=C(C(C=C3)=CC(C(F)F)=C3F)N=N2)C1 AATTXPOEAJTHHM-UHFFFAOYSA-N 0.000 claims description 2
- KVVDGKLNWZYVKX-UHFFFAOYSA-N CN1C=CN(CC2=CC=C(C(C=C3)=CC(Cl)=C3F)N=C2)C1 Chemical compound CN1C=CN(CC2=CC=C(C(C=C3)=CC(Cl)=C3F)N=C2)C1 KVVDGKLNWZYVKX-UHFFFAOYSA-N 0.000 claims description 2
- CCQJBCAJQXWMIW-UHFFFAOYSA-N CN1C=CN(CC2=CC=C(C(C=C3)=CC(Cl)=C3F)N=N2)C1 Chemical compound CN1C=CN(CC2=CC=C(C(C=C3)=CC(Cl)=C3F)N=N2)C1 CCQJBCAJQXWMIW-UHFFFAOYSA-N 0.000 claims description 2
- ZDVMVYJCCGDGJC-UHFFFAOYSA-N CN1C=CN(CC2=CC=C(C(C=C3)=CC(F)=C3F)N=C2)C1 Chemical compound CN1C=CN(CC2=CC=C(C(C=C3)=CC(F)=C3F)N=C2)C1 ZDVMVYJCCGDGJC-UHFFFAOYSA-N 0.000 claims description 2
- ZCNUWBKWELHNEA-UHFFFAOYSA-N CN1C=CN(CC2=CC=C(C(C=C3)=CC(F)=C3F)N=N2)C1 Chemical compound CN1C=CN(CC2=CC=C(C(C=C3)=CC(F)=C3F)N=N2)C1 ZCNUWBKWELHNEA-UHFFFAOYSA-N 0.000 claims description 2
- UYFUMTOBIHPKNH-UHFFFAOYSA-N CN1C=CN(CC2=CC=C(C(C=C3)=CC(OC(F)F)=C3Cl)N=N2)C1 Chemical compound CN1C=CN(CC2=CC=C(C(C=C3)=CC(OC(F)F)=C3Cl)N=N2)C1 UYFUMTOBIHPKNH-UHFFFAOYSA-N 0.000 claims description 2
- XSSQWYPJKMYVHD-UHFFFAOYSA-N CN1C=CN(CC2=CC=C(C(C=C3)=CC(OC(F)F)=C3F)N=N2)C1 Chemical compound CN1C=CN(CC2=CC=C(C(C=C3)=CC(OC(F)F)=C3F)N=N2)C1 XSSQWYPJKMYVHD-UHFFFAOYSA-N 0.000 claims description 2
- QFMFTSIQCGSZTG-UHFFFAOYSA-N CN1C=CN(CC2=CC=C(C(C=C3C(F)(F)F)=CC(F)=C3F)N=N2)C1 Chemical compound CN1C=CN(CC2=CC=C(C(C=C3C(F)(F)F)=CC(F)=C3F)N=N2)C1 QFMFTSIQCGSZTG-UHFFFAOYSA-N 0.000 claims description 2
- WDXDRLXSSNCUCP-UHFFFAOYSA-N CN1C=CN(CC2=CC=C(C(C=CC=C3C(F)(F)F)=C3F)N=C2)C1 Chemical compound CN1C=CN(CC2=CC=C(C(C=CC=C3C(F)(F)F)=C3F)N=C2)C1 WDXDRLXSSNCUCP-UHFFFAOYSA-N 0.000 claims description 2
- RNZXUFFSOFUTOZ-UHFFFAOYSA-N CN1C=CN(CC2=CC=C(C(C=CC=C3Cl)=C3F)N=C2)C1 Chemical compound CN1C=CN(CC2=CC=C(C(C=CC=C3Cl)=C3F)N=C2)C1 RNZXUFFSOFUTOZ-UHFFFAOYSA-N 0.000 claims description 2
- SJAMIXXAEYGSKM-UHFFFAOYSA-N CN1C=CN(CC2=CC=C(C3=CC(C(F)F)=CC=C3)N=N2)C1 Chemical compound CN1C=CN(CC2=CC=C(C3=CC(C(F)F)=CC=C3)N=N2)C1 SJAMIXXAEYGSKM-UHFFFAOYSA-N 0.000 claims description 2
- HTRLGCIXMRPCOC-UHFFFAOYSA-N CN1C=CN(CC2=CC=C(C3=CC(Cl)=CC=C3)N=N2)C1 Chemical compound CN1C=CN(CC2=CC=C(C3=CC(Cl)=CC=C3)N=N2)C1 HTRLGCIXMRPCOC-UHFFFAOYSA-N 0.000 claims description 2
- WREQJBKMKXCQKC-UHFFFAOYSA-N CN1C=CN(CC2=CC=C(C3=CC(F)=CC(C(F)(F)F)=C3)N=N2)C1 Chemical compound CN1C=CN(CC2=CC=C(C3=CC(F)=CC(C(F)(F)F)=C3)N=N2)C1 WREQJBKMKXCQKC-UHFFFAOYSA-N 0.000 claims description 2
- DFJCFOCSAMUXAY-UHFFFAOYSA-N CN1C=CN(CC2=CC=C(C3=CC(F)=CC(F)=C3)N=C2)C1 Chemical compound CN1C=CN(CC2=CC=C(C3=CC(F)=CC(F)=C3)N=C2)C1 DFJCFOCSAMUXAY-UHFFFAOYSA-N 0.000 claims description 2
- VOSMPYSRCHTURC-UHFFFAOYSA-N CN1C=CN(CC2=CC=C(C3=CC(F)=CC=C3)N=C2)C1 Chemical compound CN1C=CN(CC2=CC=C(C3=CC(F)=CC=C3)N=C2)C1 VOSMPYSRCHTURC-UHFFFAOYSA-N 0.000 claims description 2
- XUMWNGVMVUMMQN-UHFFFAOYSA-N CN1C=CN(CC2=CC=C(C3=CC(F)=CC=C3)N=N2)C1 Chemical compound CN1C=CN(CC2=CC=C(C3=CC(F)=CC=C3)N=N2)C1 XUMWNGVMVUMMQN-UHFFFAOYSA-N 0.000 claims description 2
- FBMJAXFQLUXRMH-UHFFFAOYSA-N CN1C=CN(CC2=CC=C(C3=CC=C(F)S3)N=N2)C1 Chemical compound CN1C=CN(CC2=CC=C(C3=CC=C(F)S3)N=N2)C1 FBMJAXFQLUXRMH-UHFFFAOYSA-N 0.000 claims description 2
- ZWHGIHVUSYKSJU-UHFFFAOYSA-N CN1C=CN(CC2=CC=NC(C(C=C3)=CC(F)=C3F)=C2)C1 Chemical compound CN1C=CN(CC2=CC=NC(C(C=C3)=CC(F)=C3F)=C2)C1 ZWHGIHVUSYKSJU-UHFFFAOYSA-N 0.000 claims description 2
- YGQQJVFXBIZXOL-UHFFFAOYSA-N CN1C=CN(CC2=CC=NC(C3=CC(F)=CC=C3)=C2)C1 Chemical compound CN1C=CN(CC2=CC=NC(C3=CC(F)=CC=C3)=C2)C1 YGQQJVFXBIZXOL-UHFFFAOYSA-N 0.000 claims description 2
- KZXPIJIXSWSTNE-UHFFFAOYSA-N CN1C=CN(CC2=NC(C(C=C3)=CC(F)=C3F)=CC=C2)C1 Chemical compound CN1C=CN(CC2=NC(C(C=C3)=CC(F)=C3F)=CC=C2)C1 KZXPIJIXSWSTNE-UHFFFAOYSA-N 0.000 claims description 2
- ICOYKJUPJKYKHR-UHFFFAOYSA-N CN1C=CN(CC2=NC(C(C=C3)=CC(F)=C3F)=CC=N2)C1 Chemical compound CN1C=CN(CC2=NC(C(C=C3)=CC(F)=C3F)=CC=N2)C1 ICOYKJUPJKYKHR-UHFFFAOYSA-N 0.000 claims description 2
- HDRMSVACMDWUFZ-UHFFFAOYSA-N CN1C=CN(CC2=NC(C(C=C3)=CC(F)=C3F)=CN=C2)C1 Chemical compound CN1C=CN(CC2=NC(C(C=C3)=CC(F)=C3F)=CN=C2)C1 HDRMSVACMDWUFZ-UHFFFAOYSA-N 0.000 claims description 2
- WEFAJCCEGUJOOY-UHFFFAOYSA-N CN1C=CN(CC2=NC(C3=CC(F)=CC=C3)=CC=C2)C1 Chemical compound CN1C=CN(CC2=NC(C3=CC(F)=CC=C3)=CC=C2)C1 WEFAJCCEGUJOOY-UHFFFAOYSA-N 0.000 claims description 2
- NGWFHSQRAXDLAM-UHFFFAOYSA-N CN1C=CN(CC2=NC(C3=CC(F)=CC=C3)=CC=N2)C1 Chemical compound CN1C=CN(CC2=NC(C3=CC(F)=CC=C3)=CC=N2)C1 NGWFHSQRAXDLAM-UHFFFAOYSA-N 0.000 claims description 2
- OPAFCVCRKWRAJU-UHFFFAOYSA-N CN1C=CN(CC2=NC(C3=CC(F)=CC=C3)=CN=C2)C1 Chemical compound CN1C=CN(CC2=NC(C3=CC(F)=CC=C3)=CN=C2)C1 OPAFCVCRKWRAJU-UHFFFAOYSA-N 0.000 claims description 2
- OBDPRFBMRLOHDB-UHFFFAOYSA-N CN1C=CN(CC2=NC=NC(C3=CC(F)=CC=C3)=C2)C1 Chemical compound CN1C=CN(CC2=NC=NC(C3=CC(F)=CC=C3)=C2)C1 OBDPRFBMRLOHDB-UHFFFAOYSA-N 0.000 claims description 2
- YYIRRRNNMYCVEK-UHFFFAOYSA-N COC(C=C(C=C1)F)=C1C(C(CN1C=CNC1)=C1)=CC=C1F Chemical compound COC(C=C(C=C1)F)=C1C(C(CN1C=CNC1)=C1)=CC=C1F YYIRRRNNMYCVEK-UHFFFAOYSA-N 0.000 claims description 2
- SSGRLDAYOHGBAG-UHFFFAOYSA-N COC(C=C1)=CC(OC)=C1C(C(CN1C=CNC1)=C1)=CC=C1F Chemical compound COC(C=C1)=CC(OC)=C1C(C(CN1C=CNC1)=C1)=CC=C1F SSGRLDAYOHGBAG-UHFFFAOYSA-N 0.000 claims description 2
- NSQNJVCEUJAKEG-UHFFFAOYSA-N COC(C=C1CN2C=CNC2)=CC=C1C(C=CC(F)=C1)=C1OC Chemical compound COC(C=C1CN2C=CNC2)=CC=C1C(C=CC(F)=C1)=C1OC NSQNJVCEUJAKEG-UHFFFAOYSA-N 0.000 claims description 2
- ZXPZOEJFFLCKJS-UHFFFAOYSA-N COC1=CC=C(C(C2)OCCN2C(CN2C=CNC2)=O)C=C1 Chemical compound COC1=CC=C(C(C2)OCCN2C(CN2C=CNC2)=O)C=C1 ZXPZOEJFFLCKJS-UHFFFAOYSA-N 0.000 claims description 2
- XUXKOORZNZHHHQ-UHFFFAOYSA-N COC1=CC=C(CN2C=CNC2)C(C2=CC(F)=CC(F)=C2)=C1 Chemical compound COC1=CC=C(CN2C=CNC2)C(C2=CC(F)=CC(F)=C2)=C1 XUXKOORZNZHHHQ-UHFFFAOYSA-N 0.000 claims description 2
- AWEZOGNGQLFXBL-UHFFFAOYSA-N COC1=CC=CC(C2=CC(F)=CC=C2CN2C=CNC2)=C1OC Chemical compound COC1=CC=CC(C2=CC(F)=CC=C2CN2C=CNC2)=C1OC AWEZOGNGQLFXBL-UHFFFAOYSA-N 0.000 claims description 2
- GXHHFFZDPSRQFJ-UHFFFAOYSA-N COC1=CC=CC(C2=CC=CC(CN3C=CNC3)=N2)=C1 Chemical compound COC1=CC=CC(C2=CC=CC(CN3C=CNC3)=N2)=C1 GXHHFFZDPSRQFJ-UHFFFAOYSA-N 0.000 claims description 2
- WVSRYECEORIFQM-UHFFFAOYSA-N ClC1=CC=CC(C2=CC=C(CN3C=CNC3)C=N2)=C1 Chemical compound ClC1=CC=CC(C2=CC=C(CN3C=CNC3)C=N2)=C1 WVSRYECEORIFQM-UHFFFAOYSA-N 0.000 claims description 2
- GCSOJMMYXMFXPJ-UHFFFAOYSA-N ClC1=CC=CC(C2=CC=CC(CN3C=CNC3)=N2)=C1 Chemical compound ClC1=CC=CC(C2=CC=CC(CN3C=CNC3)=N2)=C1 GCSOJMMYXMFXPJ-UHFFFAOYSA-N 0.000 claims description 2
- 208000028698 Cognitive impairment Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 208000012661 Dyskinesia Diseases 0.000 claims description 2
- 208000027534 Emotional disease Diseases 0.000 claims description 2
- BQVJXSDCZIYCEF-UHFFFAOYSA-N FC(C1(C2=CC(C(F)(F)F)=CC=C2)NC=C(CN2C=CNC2)C=C1)(F)F Chemical compound FC(C1(C2=CC(C(F)(F)F)=CC=C2)NC=C(CN2C=CNC2)C=C1)(F)F BQVJXSDCZIYCEF-UHFFFAOYSA-N 0.000 claims description 2
- XJRLEWSSPGEDCL-UHFFFAOYSA-N FC(C1=CC=CC(C2=CC(C(F)(F)F)=C(CN3C=CNC3)C=N2)=C1)(F)F Chemical compound FC(C1=CC=CC(C2=CC(C(F)(F)F)=C(CN3C=CNC3)C=N2)=C1)(F)F XJRLEWSSPGEDCL-UHFFFAOYSA-N 0.000 claims description 2
- BUYFPUHPKRYNRP-UHFFFAOYSA-N FC(C1=CC=CC(C2=CC(C(F)(F)F)=CC=C2CN2C=CNC2)=C1)(F)F Chemical compound FC(C1=CC=CC(C2=CC(C(F)(F)F)=CC=C2CN2C=CNC2)=C1)(F)F BUYFPUHPKRYNRP-UHFFFAOYSA-N 0.000 claims description 2
- JUNYRWJXWZEUQZ-UHFFFAOYSA-N FC(C1=CC=CC(C2=CC=C(CN3C=CNC3)C=N2)=C1)F Chemical compound FC(C1=CC=CC(C2=CC=C(CN3C=CNC3)C=N2)=C1)F JUNYRWJXWZEUQZ-UHFFFAOYSA-N 0.000 claims description 2
- HUCRMABEWIQFDW-UHFFFAOYSA-N FC(C1=CC=CC(C2=CC=CC(CN3C=CNC3)=N2)=C1)F Chemical compound FC(C1=CC=CC(C2=CC=CC(CN3C=CNC3)=N2)=C1)F HUCRMABEWIQFDW-UHFFFAOYSA-N 0.000 claims description 2
- PDXRAPVJFFRDBF-UHFFFAOYSA-N FC(C=C1)=CC=C1C1=CC=CC(CN2C=CNC2)=N1 Chemical compound FC(C=C1)=CC=C1C1=CC=CC(CN2C=CNC2)=N1 PDXRAPVJFFRDBF-UHFFFAOYSA-N 0.000 claims description 2
- WFEFUUDMFFCAQI-UHFFFAOYSA-N FC(C=CC(C1=CC=C(CN2C=CNC2)C=N1)=C1)=C1F Chemical compound FC(C=CC(C1=CC=C(CN2C=CNC2)C=N1)=C1)=C1F WFEFUUDMFFCAQI-UHFFFAOYSA-N 0.000 claims description 2
- OGUZBHZYUOAYRI-UHFFFAOYSA-N FC(C=CC(C1=CC=CC(CN2C=CNC2)=N1)=C1)=C1F Chemical compound FC(C=CC(C1=CC=CC(CN2C=CNC2)=N1)=C1)=C1F OGUZBHZYUOAYRI-UHFFFAOYSA-N 0.000 claims description 2
- KACSWIHHPXSGTB-UHFFFAOYSA-N FC(OC1=CC=CC(C(N=CC(CN2C=CNC2)=C2)=C2F)=C1)F Chemical compound FC(OC1=CC=CC(C(N=CC(CN2C=CNC2)=C2)=C2F)=C1)F KACSWIHHPXSGTB-UHFFFAOYSA-N 0.000 claims description 2
- UPPVKGYJYOONHC-UHFFFAOYSA-N FC(OC1=CC=CC(C2=CC=C(CN3C=CNC3)C=N2)=C1)F Chemical compound FC(OC1=CC=CC(C2=CC=C(CN3C=CNC3)C=N2)=C1)F UPPVKGYJYOONHC-UHFFFAOYSA-N 0.000 claims description 2
- ONLUFVNNCHYGHK-UHFFFAOYSA-N FC1=C(C2=CC(Cl)=CC=C2)N=CC(CN2C=CNC2)=C1 Chemical compound FC1=C(C2=CC(Cl)=CC=C2)N=CC(CN2C=CNC2)=C1 ONLUFVNNCHYGHK-UHFFFAOYSA-N 0.000 claims description 2
- JRAJBSAJOFHLAI-UHFFFAOYSA-N FC1=CC=C(CN2C=CNC2)C(C(C=C2)=CC(Cl)=C2F)=C1 Chemical compound FC1=CC=C(CN2C=CNC2)C(C(C=C2)=CC(Cl)=C2F)=C1 JRAJBSAJOFHLAI-UHFFFAOYSA-N 0.000 claims description 2
- BUIYMPLJQSNDDT-UHFFFAOYSA-N FC1=CC=CC(C(N=CC(CN2C=CNC2)=C2)=C2F)=C1F Chemical compound FC1=CC=CC(C(N=CC(CN2C=CNC2)=C2)=C2F)=C1F BUIYMPLJQSNDDT-UHFFFAOYSA-N 0.000 claims description 2
- AEZDOHNGOKJRBN-UHFFFAOYSA-N FC1=CC=CC(C2=CC=C(CN3C=CNC3)C=N2)=C1 Chemical compound FC1=CC=CC(C2=CC=C(CN3C=CNC3)C=N2)=C1 AEZDOHNGOKJRBN-UHFFFAOYSA-N 0.000 claims description 2
- CVQMFYZVYVEBSA-UHFFFAOYSA-N FC1=CC=CC(C2=CC=CC(CN3C=CNC3)=N2)=C1 Chemical compound FC1=CC=CC(C2=CC=CC(CN3C=CNC3)=N2)=C1 CVQMFYZVYVEBSA-UHFFFAOYSA-N 0.000 claims description 2
- 206010019196 Head injury Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000020358 Learning disease Diseases 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000037581 Persistent Infection Diseases 0.000 claims description 2
- 201000009916 Postpartum depression Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 2
- 208000029560 autism spectrum disease Diseases 0.000 claims description 2
- PBIUUJCEMUAWJJ-UHFFFAOYSA-N azetidine-3-carbonitrile Chemical compound N#CC1CNC1 PBIUUJCEMUAWJJ-UHFFFAOYSA-N 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 125000006311 cyclobutyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000006317 cyclopropyl amino group Chemical group 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 201000010901 lateral sclerosis Diseases 0.000 claims description 2
- 201000003723 learning disability Diseases 0.000 claims description 2
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000003387 muscular Effects 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 230000001932 seasonal effect Effects 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 4
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- SMWGXGDAMQMEFH-UHFFFAOYSA-N 3-(1h-imidazol-2-ylmethyl)pyridine Chemical compound C=1C=CN=CC=1CC1=NC=CN1 SMWGXGDAMQMEFH-UHFFFAOYSA-N 0.000 claims 1
- NEDSMCXQFAFVFO-UHFFFAOYSA-N 3-methyl-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-(5-methylthiophen-2-yl)imidazo[4,5-b]pyridin-2-one Chemical compound CN1C(N(C=2C1=NC=C(C=2)C=1SC(=CC=1)C)CC1=NC(=NO1)C)=O NEDSMCXQFAFVFO-UHFFFAOYSA-N 0.000 claims 1
- GZRRGDYNZLPZOQ-UHFFFAOYSA-N 3-methyl-6-(5-methylthiophen-2-yl)-1-(thiadiazol-4-ylmethyl)imidazo[4,5-b]pyridin-2-one Chemical compound CN1C(N(C=2C1=NC=C(C=2)C=1SC(=CC=1)C)CC=1N=NSC=1)=O GZRRGDYNZLPZOQ-UHFFFAOYSA-N 0.000 claims 1
- XSABOFRWWFANAZ-UHFFFAOYSA-N COC(C=C(C=C1)F)=C1C1=CC(F)=CC=C1CN1C=CNC1 Chemical compound COC(C=C(C=C1)F)=C1C1=CC(F)=CC=C1CN1C=CNC1 XSABOFRWWFANAZ-UHFFFAOYSA-N 0.000 claims 1
- XQXNKDHQLQPZBM-UHFFFAOYSA-N FC(C1=CC=CC(C(N=CC(CN2C=CNC2)=C2)=C2F)=C1)F Chemical compound FC(C1=CC=CC(C(N=CC(CN2C=CNC2)=C2)=C2F)=C1)F XQXNKDHQLQPZBM-UHFFFAOYSA-N 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- QMHIMXFNBOYPND-UHFFFAOYSA-N 4-methylthiazole Chemical compound CC1=CSC=N1 QMHIMXFNBOYPND-UHFFFAOYSA-N 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- AQHMTCPTISMGLO-UHFFFAOYSA-N CC(C(F)=C(C=C1)C2=C(CN3C=CN(C)C3)C=NC=N2)=C1F Chemical compound CC(C(F)=C(C=C1)C2=C(CN3C=CN(C)C3)C=NC=N2)=C1F AQHMTCPTISMGLO-UHFFFAOYSA-N 0.000 description 1
- ULHYXERKHINLGB-UHFFFAOYSA-N CN1C=CN(CC2=CC=C(C3=CC(C(F)F)=CC=C3)N=C2)C1 Chemical compound CN1C=CN(CC2=CC=C(C3=CC(C(F)F)=CC=C3)N=C2)C1 ULHYXERKHINLGB-UHFFFAOYSA-N 0.000 description 1
- VWXNHZLWXIABKQ-UHFFFAOYSA-N CN1C=CN(CC2=CC=C(C3=CC=C(C(F)F)S3)N=N2)C1 Chemical compound CN1C=CN(CC2=CC=C(C3=CC=C(C(F)F)S3)N=N2)C1 VWXNHZLWXIABKQ-UHFFFAOYSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- ZSCOJHBARLBZGT-UHFFFAOYSA-N FC(C1=CC=CC(C2=C(C(F)(F)F)C=C(CN3C=CNC3)C=N2)=C1)(F)F Chemical compound FC(C1=CC=CC(C2=C(C(F)(F)F)C=C(CN3C=CNC3)C=N2)=C1)(F)F ZSCOJHBARLBZGT-UHFFFAOYSA-N 0.000 description 1
- WXCTZRLJAZIDIL-UHFFFAOYSA-N FC(C=C1)=CC=C1C1=CC=C(CN2C=CNC2)C=N1 Chemical compound FC(C=C1)=CC=C1C1=CC=C(CN2C=CNC2)C=N1 WXCTZRLJAZIDIL-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404798P | 2016-10-06 | 2016-10-06 | |
| US62/404,798 | 2016-10-06 | ||
| PCT/US2017/055278 WO2018067786A1 (en) | 2016-10-06 | 2017-10-05 | Substituted 1h-imidazo[4,5-b]pyridin-2(3h)-ones and their use as glun2b receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019530695A JP2019530695A (ja) | 2019-10-24 |
| JP2019530695A5 true JP2019530695A5 (https=) | 2020-11-12 |
| JP7001682B2 JP7001682B2 (ja) | 2022-01-19 |
Family
ID=61831306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518219A Active JP7001682B2 (ja) | 2016-10-06 | 2017-10-05 | 置換１Ｈ－イミダゾ［４，５－ｂ］ピリジン－２（３Ｈ）－オン及びＧＬＵＮ２Ｂ受容体調節因子としてのそれらの使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US10617676B2 (https=) |
| EP (1) | EP3523311B1 (https=) |
| JP (1) | JP7001682B2 (https=) |
| KR (1) | KR20190056435A (https=) |
| CN (2) | CN110062761B (https=) |
| AR (1) | AR109810A1 (https=) |
| AU (1) | AU2017340602A1 (https=) |
| BR (1) | BR112019006691A2 (https=) |
| CA (1) | CA3038820A1 (https=) |
| CL (1) | CL2019000882A1 (https=) |
| EA (1) | EA201990848A1 (https=) |
| ES (1) | ES2950881T3 (https=) |
| IL (1) | IL265757A (https=) |
| MA (1) | MA46470A (https=) |
| MX (1) | MX2019003980A (https=) |
| PH (1) | PH12019500676A1 (https=) |
| TW (1) | TW201819376A (https=) |
| WO (1) | WO2018067786A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016025917A1 (en) | 2014-08-15 | 2016-02-18 | Janssen Pharmaceuticals, Inc. | Triazoles as nr2b receptor inhibitors |
| ES2791252T3 (es) | 2014-08-15 | 2020-11-03 | Janssen Pharmaceuticals Inc | Pirazoles |
| HRP20200410T1 (hr) | 2015-07-09 | 2020-08-21 | Janssen Pharmaceutica Nv | Supstituirani 4-azaindoli i njihova upotreba kao modulatora glun2b receptora |
| BR112018016329A2 (pt) | 2016-02-10 | 2018-12-18 | Janssen Pharmaceutica Nv | 1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| US11261188B2 (en) | 2016-11-28 | 2022-03-01 | Praxis Precision Medicines, Inc. | Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel |
| DK3548033T3 (da) | 2016-11-28 | 2024-07-15 | Praxis Prec Medicines Inc | Forbindelser og deres fremgangsmåde til anvendelse |
| US11492345B2 (en) * | 2017-02-13 | 2022-11-08 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2018187480A1 (en) | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2019035951A1 (en) | 2017-08-15 | 2019-02-21 | Praxis Precision Medicines, Inc. | COMPOUNDS AND THEIR METHODS OF USE |
| WO2019193516A2 (en) | 2018-04-04 | 2019-10-10 | Janssen Pharmaceutica Nv | Substituted pyridine and pyrimidines and their use as glun2b receptor modulators |
| WO2019232209A1 (en) | 2018-05-30 | 2019-12-05 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| EA202092908A1 (ru) | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
| CN109499614B (zh) * | 2018-12-12 | 2021-06-04 | 怀化学院 | MOPs负载双齿螯合型金属催化剂及其制备方法 |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| AU2020293642A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators |
| SG11202112405VA (en) | 2019-06-14 | 2021-12-30 | Janssen Pharmaceutica Nv | Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators |
| JP7667097B2 (ja) * | 2019-06-14 | 2025-04-22 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用 |
| KR20220024403A (ko) * | 2019-06-14 | 2022-03-03 | 얀센 파마슈티카 엔.브이. | 치환된 피라졸로-피라진 및 이들의 glun2b 수용체 조절제로서의 용도 |
| CN113993868A (zh) | 2019-06-14 | 2022-01-28 | 詹森药业有限公司 | 取代的吡唑并吡啶酰胺以及它们作为glun2b受体调节剂的用途 |
| CN113950357A (zh) | 2019-06-14 | 2022-01-18 | 詹森药业有限公司 | 吡嗪氨基甲酸酯及其作为GluN2B受体调节剂的用途 |
| MX2021015508A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Carbamatos de piridina y su uso como moduladores del receptor glun2b. |
| US12552797B2 (en) | 2019-11-27 | 2026-02-17 | Praxis Precision Medicines, Inc. | Process for making (3-[cyclopropylethoxy(difluoro)methyl]-6-6[5-fluoro-6-(2,2,2-trifluoroethoxy-3-pyridyl]- [1,2,4]triazolo[4,3-a]pyrazine |
| AU2021233745B2 (en) * | 2020-03-11 | 2024-05-02 | Anygen Co., Ltd. | Composition for anti-diabetes and anti-obesity comprising novel compound |
| BR112022023559A2 (pt) * | 2020-05-21 | 2023-01-24 | Stemsynergy Therapeutics Inc | Inibidores de notch e seus usos |
| CN112939986B (zh) * | 2021-02-18 | 2023-06-13 | 新乡医学院 | 一种吡唑并嘧啶类化合物的合成方法 |
| KR20230037391A (ko) * | 2021-09-09 | 2023-03-16 | 애니젠 주식회사 | 신규한 화합물을 포함하는 염증성 장질환 예방 또는 치료용 조성물 |
| MX2024013240A (es) | 2022-04-26 | 2024-12-06 | Praxis Prec Medicines Inc | Tratamiento de trastornos neurologicos |
| WO2025224308A1 (en) * | 2024-04-25 | 2025-10-30 | Scenic Immunology B.V. | Qpctl inhibitors |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9407447D0 (en) | 1994-04-14 | 1994-06-08 | Glaxo Group Ltd | Chemical compounds |
| CA2262502C (en) | 1996-07-31 | 2002-11-26 | Nikken Chemicals Co., Ltd. | 6-phenyltetrahydro-1,3-oxazin-2-one derivatives and pharmaceutical composition containing the same |
| AU2001270149A1 (en) * | 2000-06-26 | 2002-01-08 | Merck & Co., Inc. | Iminopyrimidine nmda nr2b receptor antagonists |
| US6610723B2 (en) | 2001-01-29 | 2003-08-26 | Hoffmann-La Roche Inc. | Imidazole derivatives |
| EP1490364B1 (en) | 2002-03-28 | 2007-09-26 | Eisai R&D Management Co., Ltd. | 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders |
| US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| CA2482838A1 (en) * | 2002-05-31 | 2003-12-11 | Eisai Co., Ltd. | Pyrazole compounds and pharmaceutical compositions containing the compound |
| EP1720860A1 (en) | 2004-02-18 | 2006-11-15 | AstraZeneca AB | Triazole compounds and their use as metabotropic glutamate receptor antagonists |
| US7820654B2 (en) | 2004-09-23 | 2010-10-26 | Dr. Reddy's Laboratories Ltd. | Pyrimidine compounds, process for their preparation and compositions containing them |
| US7807704B2 (en) | 2006-03-30 | 2010-10-05 | Chemocentryx, Inc. | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| TWI443090B (zh) | 2007-05-25 | 2014-07-01 | Abbvie Deutschland | 作為代謝性麩胺酸受體２（ｍｇｌｕ２ 受體）之正向調節劑之雜環化合物 |
| WO2009004430A1 (en) | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
| CN101842357A (zh) | 2007-08-30 | 2010-09-22 | 武田药品工业株式会社 | 取代的吡唑衍生物 |
| EP2215073A4 (en) | 2007-10-31 | 2011-04-06 | Merck Sharp & Dohme | SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS |
| WO2009118187A1 (en) | 2008-03-27 | 2009-10-01 | Evotec Neurosciences Gmbh | Methods for treating disorders using nmda nr2b-subtype selective antagonist |
| JPWO2009157196A1 (ja) | 2008-06-25 | 2011-12-08 | 武田薬品工業株式会社 | アミド化合物 |
| NZ590688A (en) | 2008-08-05 | 2012-09-28 | Daiichi Sankyo Co Ltd | imidazo[4,5-b]pyridin-2-one derivatives |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| RU2517181C2 (ru) | 2008-10-16 | 2014-05-27 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов |
| CA2744498C (en) * | 2008-11-25 | 2017-10-24 | University Of Rochester | Mlk inhibitors and methods of use |
| US8969342B2 (en) | 2009-03-20 | 2015-03-03 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| EP2579717A4 (en) * | 2010-06-09 | 2013-12-11 | Merck Sharp & Dohme | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 |
| JP2012188363A (ja) * | 2011-03-09 | 2012-10-04 | Dainippon Sumitomo Pharma Co Ltd | アザベンゾイミダゾロン誘導体 |
| WO2013060029A1 (en) | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp | Allosteric modulators of metabotropic glutamate receptors |
| WO2013130855A1 (en) | 2012-03-02 | 2013-09-06 | Takeda Pharmaceutical Company Limited | Indazole derivatives |
| MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| WO2014124651A1 (en) | 2013-02-15 | 2014-08-21 | Københavns Universitet | Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists |
| TW201444820A (zh) | 2013-03-13 | 2014-12-01 | Abbvie Inc | 吡啶ｃｄｋ９激酶抑制劑 |
| SG11201506687RA (en) | 2013-03-15 | 2015-09-29 | Plexxikon Inc | Heterocyclic compounds and uses thereof |
| CA2915838C (en) | 2013-06-21 | 2023-04-18 | Zenith Epigenetics Corp. | Bicyclic bromodomain inhibitors |
| CA2918242C (en) | 2013-07-31 | 2022-06-21 | Merck Patent Gmbh | Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof |
| WO2016015097A1 (en) | 2014-07-28 | 2016-02-04 | Safemate Australia Pty Ltd | Systems and methods for making personal emergency information available to third parties |
| ES2791252T3 (es) | 2014-08-15 | 2020-11-03 | Janssen Pharmaceuticals Inc | Pirazoles |
| WO2016025917A1 (en) | 2014-08-15 | 2016-02-18 | Janssen Pharmaceuticals, Inc. | Triazoles as nr2b receptor inhibitors |
| US12006328B2 (en) | 2014-11-18 | 2024-06-11 | Emory University | Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto |
| MA41803A (fr) | 2015-03-24 | 2018-01-30 | Almirall Sa | Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques |
| HRP20200410T1 (hr) * | 2015-07-09 | 2020-08-21 | Janssen Pharmaceutica Nv | Supstituirani 4-azaindoli i njihova upotreba kao modulatora glun2b receptora |
| BR112018016329A2 (pt) | 2016-02-10 | 2018-12-18 | Janssen Pharmaceutica Nv | 1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| IL271149B2 (en) | 2017-06-14 | 2024-05-01 | Trevena Inc | Compounds for modulating s1p1 activity and methods of using the same |
| WO2019193516A2 (en) | 2018-04-04 | 2019-10-10 | Janssen Pharmaceutica Nv | Substituted pyridine and pyrimidines and their use as glun2b receptor modulators |
| CN110294756A (zh) | 2019-06-04 | 2019-10-01 | 广州市原子高科同位素医药有限公司 | GluN2B亚基靶向型中枢神经系统正电子示踪剂及其制备 |
| MX2021015508A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Carbamatos de piridina y su uso como moduladores del receptor glun2b. |
| SG11202112405VA (en) | 2019-06-14 | 2021-12-30 | Janssen Pharmaceutica Nv | Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators |
| CN113950357A (zh) | 2019-06-14 | 2022-01-18 | 詹森药业有限公司 | 吡嗪氨基甲酸酯及其作为GluN2B受体调节剂的用途 |
| KR20220024403A (ko) | 2019-06-14 | 2022-03-03 | 얀센 파마슈티카 엔.브이. | 치환된 피라졸로-피라진 및 이들의 glun2b 수용체 조절제로서의 용도 |
| AU2020293642A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators |
| CN113993868A (zh) | 2019-06-14 | 2022-01-28 | 詹森药业有限公司 | 取代的吡唑并吡啶酰胺以及它们作为glun2b受体调节剂的用途 |
-
2017
- 2017-10-03 TW TW106134127A patent/TW201819376A/zh unknown
- 2017-10-05 US US15/725,500 patent/US10617676B2/en active Active
- 2017-10-05 JP JP2019518219A patent/JP7001682B2/ja active Active
- 2017-10-05 MX MX2019003980A patent/MX2019003980A/es unknown
- 2017-10-05 CN CN201780075930.5A patent/CN110062761B/zh active Active
- 2017-10-05 CN CN202210460371.2A patent/CN114989164B/zh active Active
- 2017-10-05 AU AU2017340602A patent/AU2017340602A1/en not_active Abandoned
- 2017-10-05 WO PCT/US2017/055278 patent/WO2018067786A1/en not_active Ceased
- 2017-10-05 ES ES17859165T patent/ES2950881T3/es active Active
- 2017-10-05 CA CA3038820A patent/CA3038820A1/en active Pending
- 2017-10-05 EP EP17859165.7A patent/EP3523311B1/en active Active
- 2017-10-05 MA MA046470A patent/MA46470A/fr unknown
- 2017-10-05 BR BR112019006691A patent/BR112019006691A2/pt not_active Application Discontinuation
- 2017-10-05 AR ARP170102779A patent/AR109810A1/es unknown
- 2017-10-05 EA EA201990848A patent/EA201990848A1/ru unknown
- 2017-10-05 KR KR1020197012678A patent/KR20190056435A/ko not_active Withdrawn
-
2019
- 2019-03-28 PH PH12019500676A patent/PH12019500676A1/en unknown
- 2019-04-01 IL IL265757A patent/IL265757A/en unknown
- 2019-04-02 CL CL2019000882A patent/CL2019000882A1/es unknown
-
2020
- 2020-03-03 US US16/807,385 patent/US11207298B2/en not_active Expired - Fee Related
-
2021
- 2021-09-14 US US17/474,631 patent/US11759455B2/en active Active
-
2023
- 2023-06-29 US US18/344,169 patent/US20230338341A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019530695A5 (https=) | ||
| JP2011500806A5 (https=) | ||
| IL263511A (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| JP2018520170A5 (https=) | ||
| JP2017500364A5 (https=) | ||
| JP2019523233A5 (https=) | ||
| JP2016523911A5 (https=) | ||
| JP2017502049A5 (https=) | ||
| JP2015500332A5 (https=) | ||
| JP2019537571A5 (https=) | ||
| RU2014139601A (ru) | Ингибиторы серин/треониновых киназ | |
| JP2014521711A5 (https=) | ||
| JP2019504854A5 (https=) | ||
| IL258577A (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
| JP2016519096A5 (https=) | ||
| JP2016523976A5 (https=) | ||
| CA2515197A1 (en) | Pyrazolopyridine derivates | |
| JP2009542638A5 (https=) | ||
| RU2017120855A (ru) | Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина | |
| JP2017528515A5 (https=) | ||
| JP2013533868A5 (https=) | ||
| JP2020503302A5 (https=) | ||
| JP2017523214A5 (https=) | ||
| JP2017523223A5 (https=) | ||
| JP2020502230A5 (https=) |